Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Calidi Biotherapeutics, Inc.

Calidi to Effect Reverse Stock Split
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers CLDI
Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
From Calidi Biotherapeutics, Inc.
Via Business Wire
Tickers FLAG
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs
From Calidi Biotherapeutics, Inc.
Via Business Wire
Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit
From Calidi Biotherapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.